← Back to Search

Horizons Group for Quality of Life

N/A

Recruiting

Led By Lara Traeger, PhD

Research Sponsored by University of Miami

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Have moderate to severe chronic graft versus host disease

Currently receiving care at the Sylvester Comprehensive Cancer Center Bone Marrow Transplant Program

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline (pre-intervention) to 10-week follow-up

Awards & highlights

Study Summary

This trial tests if a group therapy program can improve quality of life for people with GvHD.

Who is the study for?

This trial is for patients who had a stem cell transplant and are now dealing with moderate to severe chronic graft-versus-host disease. They must be getting care at the Sylvester Comprehensive Cancer Center Bone Marrow Transplant Program and able to join group sessions in English or Spanish. Pregnant women, prisoners, or those with conditions that affect understanding or participation are excluded.Check my eligibility

What is being tested?

The Horizons Program, a group-based behavioral intervention designed to improve life quality for patients suffering from chronic graft-versus-host disease after stem cell transplantation, is being tested for its practicality.See study design

What are the potential side effects?

Since this study focuses on a behavioral intervention rather than medication, traditional side effects like you'd see with drugs aren't expected. However, participants may experience emotional discomfort discussing their condition.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have moderate to severe chronic graft versus host disease.

Select...

I am currently a patient at the Sylvester Comprehensive Cancer Center Bone Marrow Transplant Program.

Select...

I have had a stem cell transplant from a donor.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline (pre-intervention) to 10-week follow-up

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline (pre-intervention) to 10-week follow-up

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (pre-intervention) to 10-week follow-up for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Percentage of participant attendance

Percentage of participant enrollment

Percentage of participant retention

Trial Design

1Treatment groups

Experimental Treatment

Group I: Horizons GroupExperimental Treatment1 Intervention

Participants will receive the Horizons Group intervention for up to 8 weeks.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of MiamiLead Sponsor

902 Previous Clinical Trials

410,056 Total Patients Enrolled

Lara Traeger, PhDPrincipal InvestigatorUniversity of Miami

3 Previous Clinical Trials

403 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research endeavor accepting new participants?

"As per the information provided on clinicaltrials.gov, this trial has ceased its patient recruitment efforts. The initial posting date was March 1st 2024 and the last update occured November 29th 2023. Fortunately, there are 471 other trials with open enrollment currently available for candidates to consider."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Horizons Chronic Graft-Versus-Host-Disease Study

Lara Traeger 2023. "Horizons Chronic Graft-Versus-Host-Disease Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06160986.

All > Graft Vs Host Disease